Nanalysis Eyes a Stronger Second Half as EBITDA Turns Positive Trajectory

Q2 2026 shows margin expansion and cost discipline; new board blood and tariff immunity set the stage.

NSCIF · Earnings Call · 2026-08-24

A Quarter of Quiet Progress

Nanalysis Scientific's Q2 2026 results, reported on August 24, show a company executing a disciplined turnaround. Consolidated revenue edged up 1.5% to C$9.72 million, but the more telling numbers are the adjusted EBITDA improvement of C$1.34 million to C$881 thousand and a narrowing net loss to C$666 thousand. As CFO Heather Kury put it: “The improvement was primarily attributable to improved operational performance, which included increased security services customer service, lower sales, marketing, general and administrative expenses, which included ensuring that all eligible investment tax credits have been filed.” — Heather Kury · 2026-08-24 The gross margin story is equally encouraging: product margins improved to 65% from 61%, and security services margins to 12% from 10%, driven by better logistics and overtime management. This is the result of a focused effort on cost structure and operational efficiency.

Operational Reshaping

CEO Sean Krakiwsky emphasized the ongoing transformation of the sales and dealer network. The benchtop NMR spectrometers remain the core technology, and the company has substantially reorganized its international dealer network in territories like Japan, the UK, India, and China. A revamped direct sales organization is expected to bear fruit in the coming months. Krakiwsky also highlighted the contributions of Marc Tomlinson to the services business, though the full impact is still to come. The company continues to invest in innovation, but R&D spending is partially offset by government subsidies. Krakiwsky noted: “Do not be fooled by that small number you see on the income statement. If you want, contact me or look in the notes, and you will see we still spend a healthy amount on innovation.” — Sean Krakiwsky · 2026-08-24

Macro Tailwinds and a New Board Voice

Perhaps the most notable change is the addition of Dr. Werner Maas, former president of Bruker BioSpin, to the board. His insight aligns with the company's outlook: instrumentation companies had a weak first half, but the second half is expected to improve materially. Krakiwsky linked this to budget stalls in the US and their global ripple effects. He offered a tangible benchmark:

If you remember what our Q4 numbers were in 2024... you can see that kind of foreshadows what our potential is. Now the reason why we were not able to keep that potential is because we had to shed some businesses because of our legacy issues associated with acquisitions and then the macro and uncertainty came in with the Trump tariffs and so on.
Sean Krakiwsky · 2026-08-24

In a unique twist for a Canadian company, Nanalysis is explicitly exempt from the tariffs dominating headlines. Krakiwsky confirmed: “I just want to confirm to everybody that we are exempt from any of these tariffs that are being discussed in the popular media.” — Sean Krakiwsky · 2026-08-24 This differentiates it from the wave of tariff-refund discussions seen among recent reporters like Walmart and Target.

Continuity and Expectation

This quarter echoes prior calls — the same themes of margin expansion and partnership potential are present. But the tone is more confident. In the May 2025 call, Krakiwsky lamented that US government orders were in a holding pattern: “customers like the FDA and the EPA are customers of ours that we expected significant orders in Q1 but they've kind of gone into a holding pattern.” — Sean Krakiwsky, Chief Executive Officer · 2025-05-28 Now, he points to a pipeline that is "exciting" and expects improvements starting in Q3. The company is clearly positioning itself for a step change in the second half, powered by a leaner cost base and a stronger sales engine. Even amid the optimism, the long-term vision remains intact. As Krakiwsky said in an earlier call: “We're just scratching the surface here in the first inning of a nine-inning game.” — Sean Krakiwsky, President & COO · 2024-11-21 That mindset is now paired with a more concrete financial footing. The security services business is generating higher-margin project work, and the product side is seeing renewed momentum from the dealer overhaul. With a new board director steeped in industry cycles and an explicit tariff exemption, Nanalysis is betting that the second half of 2026 will finally translate operational improvements into sustained profitability. For a company with a market cap under C$14 million, the path is narrow but clear. If the macro environment cooperates, the Q4-2024 benchmark could become a launchpad rather than a distant memory. Investors watching the tape may be waiting for the revenue inflection, but the groundwork laid in Q2 is a necessary first step.